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Abstract
The search for new targeted therapies to improve the quality of life of patients 
with pancreatic cancer has taken about 30 years. Compounds that can inhibit the 
K-Ras4B oncoprotein signaling pathway have been sought. Taking into account that 
the interaction of KRas4B with PDE6δ is essential for its transport and subsequent 
activation in the plasma membrane, our working group identified and evaluated 
in vitro and in vivo small organic molecules that could act as molecular staples to 
stabilize the KRas4B/PDE6δ heterodimeric complex. From this group of molecules, 
38 compounds with high interaction energies on the structure of the crystallized 
molecular complex were selected, indicating that they efficiently stabilized the 
molecular complex. In vitro evaluation of compounds called D14, C22, and C19 
showed significant specific effects on the cell viability of pancreatic cancer cells 
(and not on normal cells), thus inducing death by apoptosis and significantly 
inhibiting the activation of the pathways, signaling AKT and ERK. In addition to 
these experimental findings, we were also able to detect that compounds D14 and 
C22 showed significant tumor growth inhibitory activity in pancreatic cancer cell-
induced subcutaneous xenograft models.




About 95% of the pancreatic ductal adenocarcinoma (PDAC) originates in the 
exocrine pancreas, and 5% is generated in the endocrine pancreas. There are several 
precursors for the development of PDAC; among them, noninfiltrating lesions, 
called pancreatic intraepithelial neoplasia or PanIN [1], are remarkable. The follow-
up of the PanIN toward an infiltrating lesion is given by the abnormal distribution 
inside the pancreas. These lesions can be located in the pancreatic parenchyma, 
which causes its infiltration. Currently, the development of a pancreatic adeno-
carcinoma is monitored by measuring the overexpression of EGFR, KRAS, MUC1, 
and MUC4 genes or the inactivation of INK4A, TP53, and BRCA2 genes, which are 
essential for proper cell functioning [1–4, 5–8].
The invasive ductal adenocarcinoma is the most common pancreatic neoplasm, 
as it occurs in 85% of the cases. Eighty percent of the patients with this type of 
neoplasm have an average survival of 3–6 months after the detection; that is why 
this adenocarcinoma has been proposed as one of the most deadly existing [1, 
9–11]. The invasive micro ductal adenocarcinoma deforms the small pancreatic 
glands, infiltrates the stroma, and triggers a fibrous coating, where 98% of the cases 
present mutations in the KRas4B gene [2, 10]. One of the most important factors 
for the development, maintenance, and progression of this disease is the presence 
of mutations in the KRas4B oncoprotein, which is mutated in 99% of PDAC cases 
[12]. Kras4B is a small GTPase, which belongs to the RAS protein subfamily, and it 
has essential functions in the control and regulation of normal cell proliferation. 
Human tumors almost always express mutated KRas4B proteins, from 90 to 99% of 
cases; specific mutations of this protein occur in codons 12, 13, or 61, which leaves 
the KRas4B protein constitutively active [11]. The active state of KRas4B proteins 
contributes significantly to develop the malignant phenotype, such as the deregula-
tion of tumor cell growth, the evasion of programmed cell death, invasion, and 
angiogenesis [13]. There are three genes that code for RAS proteins in the mam-
malian genome: HRas, NRas, and KRas; four isoforms are obtained by alternative 
splicing: H-Ras, N-Ras, K-Ras4A, and K-Ras4B [14].
RAS subfamily proteins are also members of a broad class of proteins known as 
CAAX proteins [15] like this because the C-terminal end sequence has the CAAX 
amino acids (C: cysteine, A: aliphatic amino acid, and X: any amino acid), and this 
sequence is modified post-translationally in order to confer Ras protein affinity 
for the plasma membrane (for its subsequent activation). This process is regulated 
by three enzymes that work sequentially: first, the farnesyltransferase enzyme 
participates in the prenylation of the CAAX sequence; second, a protein called Ras-
converting enzyme (RCE1) cleaves the last two amino acids of the CAAX sequence; 
third, a methyltransferase (ICMT) allows adding a methyl group to the carboxyl of 
the cysteine terminal to finally generate the mature RTP GTPase [16]. Farnesylation 
in the 185 cysteine terminal allows Ras proteins to increase their affinity for cell 
membranes and for many farnesyl group binding proteins that are analogous to 
RhoGDI transporters, such as phosphodiesterase 6 delta subunit (PDE6δ), which 
has been described as an indispensable molecule in the traffic of some GTPases of 
the Ras family [14, 17]. After the findings about the presence of KRas4B and its 
importance in the formation, maintenance, and progression of the most deadly 
neoplasms such as the PDAC [18, 19], studies have been conducted to discover and 
develop pharmacological inhibitors against oncogenic KRas4B. The approaches 
include: (a) finding small molecules that interact with KRas4B directly in order to 
prevent its activation [18, 19]; (b) finding enzyme inhibitors responsible for the 
post-translational modifications in order to prevent the transport of KRas4B to the 
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plasma membrane; (c) finding compounds that inhibit the KRas4B downstream 
signaling pathway, as well as autophagy inhibitors and inhibitors of neoplastic cell 
metabolism [18, 19].
Despite the enormous prevalence of Kras4B mutations in pancreatic cancer, an 
efficient targeted treatment against aberrant signaling of this oncoprotein has not 
been found. It is known that pancreatic cancer cells with mutated Kras4B exhibit 
a phenomenon called “oncogene addiction”, in which their survival becomes 
dependent on Kras4B signaling. Therefore, the inhibition of the Kras4B function 
promotes the inhibition of the viability of cancer cells; this eventually leads to 
cell death by apoptosis and the regression of the tumor [20, 21]. Therefore, it is 
necessary to find new strategies that allow us to inhibit the molecular mechanisms 
of activation and/or signaling of mutated Kras4B in pancreatic cancer. In this 
chapter, we describe new organic molecules that inhibit the dissociation of the 
heterodimeric molecular complex KRas4BG12C-D/PDE6δ; thus promoting that 
KRas4BG12C/D cannot bind to the plasma membrane, and consequently, it cannot 
be activated in pancreatic tumor cells.
2. Targeted drugs for the inhibition of KRas4B
The direct inhibition of KRas4B has been a difficult task. Sites susceptible 
to pharmacological interaction have been identified by means of bioinformatic 
programs; therefore, compounds such as SCH-53239 and its analogue SCH-54292, 
which presented low affinity with respect to KRas4B, have been identified. These 
compounds were designed to interact with the Switch II of KRas4B, competing 
with the GDP. These compounds have in their chemical structure a hydroxylamine, 
which is essential for their cytotoxic activity. These compounds present a high level 
of toxicity in murine models, so they are in the improvement phase [22]. In 2012, 
several research groups reported a compound called DCAI [22, 23], which interacts 
with KRas4B at the site located between the α2 helix and β4 loop; this compound was 
able to inhibit the interaction of SOS1 with KRas4B with an IC50 of 340 μM, having an 
EC50 of 15.8 μM; therefore, it is so far one of the compounds considered for the treat-
ment of PDAC [22, 23]. Also, different research teams have been working on 11,000 
analogues of the DCAI compound in silico, based on the nuclear magnetic resonance 
(NMR). One of the analogues called VU0460009, showed an IC50 of 240 μM; 
although the concentration of the mean inhibition decreased, this compound did not 
have a considerable effect in murine models, so it was not possible to consider it as a 
candidate for treatment of PDAC [22, 23]. In order to find an organic compound that 
was capable of inhibiting the activation of KRas4B, studies were conducted to direct a 
specific molecule to the location site of the KRas4BG12C mutation, which is the most 
frequent in lung cancer [22]. One of the compounds studied was the so-called SCH-
54292 [12], which is capable of binding to the α2 and α3 helices of KRas4B. This com-
pound showed activity only in the cell lines that present KRas4BG12C, and with this 
finding, the researchers have intended to identify and study the analogues of SCH-
54292 with the greatest effect on cancer cell lines [12]. Another group of researchers 
created a GDP analogue called SML-8-73-1, which could covalently bind to the cyste-
ine  of KRas4BG12C without taking into account the affinity of GDP with its binding 
site in KRas4B. These compounds did not show the expected effect on lung cancer 
cell lines, so they are in the improvement phase [22]. In recent years, several research 
groups have been trying to selectively inhibit mutated KRas activation and signaling. 
One way to prevent the activation of KRas and, therefore, its effector pathways, is 
through allosteric inhibition. Consequently, several research groups have developed 
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experimental models based on the in silico search for compounds that selectively bind 
and inhibit KRas. This strategy was carried out with an initial virtual coupling test of 
a library of compounds based on the reconstructed pocket structure of the switch I 
of RAS crystal, which resulted in an in silico coupling based on the pocket structure. 
The pocket consists of a hydrophilic part, which is composed of negatively charged 
residues such as Glu47, Asp48, and Asp 67, and a hydrophobic part, which consists of 
Leu66, Met77, and Tyr 81; on its surface, it is partially bordered by charged residues 
such as Lys15 and Asp67. These structural characteristics were used to establish a 
pharmacophore for the screening of charged residues, such as Asp67 (which corre-
sponds to Asp57 of Ras), located in the lower center of the hydrophilic pocket in order 
to ensure the specificity of binding and energy. After the coupling analysis, com-
pounds that in vitro effectively decreased the activation of Ras as well as its effectors 
were detected [21]. The development of small molecules that irreversibly bind to the 
oncogenic mutant KRasG12C allows the interruption of switch-1, and this alters the 
preference of native nucleotides in order to favor GDP over GTP and, consequently, 
this prevents its binding with the Raf effector. On the other hand, and using a similar 
strategy of in silico analysis and development of analogues with a favorable balance 
of ADME attributes (absorption, distribution, metabolism, and excretion), in vivo 
stability and specificity, in 2018, Janes and collaborators reported the design and 
characterization of switch-IIP inhibitors of KRasG12C with enhanced potency and 
pharmacological properties. Using tests based on liquid chromatography-tandem 
mass spectrometry (LC/MS-MS), compounds that covalently bound to Cys12 of 
K-Ras were measured directly and quantitatively. Pharmacological inhibition of 
KRasG12D with compound ARS-1620 suppressed the growth of cancer cells. ARS-
1620 exhibited excellent oral bioavailability in mice and sufficient blood stability and, 
importantly, induces tumor regression through a specific mechanism of action.
Another strategy, proposed by Zeng and collaborators in 2017, is the possibility 
of designing compounds that incorporate elements of both the switch-IIP and the 
guanosine pharmacophores, or through the development of bivalent compounds 
that could recruit ligases to promote the degradation of RAS mediated by ubiquiti-
nation. The compounds were prepared with fluorophenyl and piperazinyl substitu-
ents and an electrophilic acrylamide warhead attached to the piperazine in order 
to effectively bind to KRasG12C. Subsequently, the 1_AM analogue was developed 
with an amino amide substituent and showed a more complete binding with KRas. 
In addition, 1_AM was compared with its serial head [1], and its properties were 
examined in H358 cells. The 1_AM inhibitor decreased levels of KRas bound to GTP 
by ~80% compared to the performance of inhibitor 1, and likewise the decrease of 
the ERK effector phosphorylated.
An interesting strategy, which has been recently addressed, is the blocking 
of the interaction of RAS with its effector Raf. A cyclic peptide called cyclosarin 
9A5 blocked the RAS-RAF interaction. The amino acids present in cyclosarin such 
as nal, Fpa, Thr, norleucine (nle), and Trp are critical for binding with KRas. 
Cyclosarin 9A5 showed improved cell permeability and an affinity for KRas with 
an IC50 = 0.12 μM. Cyclosarin reduced the proliferation and induced cell death by 
apoptosis in tumor cells with mutated KRas [24].
Similarly, in 2019, MacCarthy and collaborators used a variety of computational 
approaches in order to describe four binding sites in K-Ras for allosteric ligands. 
The new inhibitors bind to the pocket p1 with submicromolar affinity and function 
primarily by directly inhibiting the interaction of KRas with its effector proteins. 
This potential inhibitor forms multiple favorable interactions with residues in 
the pocket p1 of nonmutated KRas (WT) and with residues of the mutants of 
K-RasG12D, G12C, and Q61H in the active state bound to GTP. In addition, the 
authors report that the inhibitor of KRas binding to its effectors decreases the 
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levels of phosphorylation of ERK and cRAF in BHK cells that express the mutant of 
KRasG12D and G12V, which suggests the inhibition of KRas signaling through the 
MAPK pathway. However, the problem of allosteric KRas inhibitors that prevent 
interaction with their effectors is that they do not exhibit selectivity toward a 
particular RAS isoform or KRas WT vs. mutated KRas, which raises the toxicity 
problem in cells and therefore in healthy organs when they are used in vivo.
Another approach to inhibit the interaction of KRas with its effectors is the 
search for macromolecules that selectively bind to KRas at an allosteric lobe site that 
encompasses histidine 95 residue at the interface between the helix α3/loop 7/helix 
α4. Designed ankyrine repeat proteins (DARPins) K13 and K219 inhibit the interac-
tions with the effectors and the nucleotide exchange of KRas. Similarly, K13 and 
K19 induce selective inhibition of the RAF/MEK/ERK signaling pathway in cells 
with the Kras4BG13D mutation but not in cells with other mutated isoforms such as 
HRasG12V and/or RAS WT. This suggests that K13 and K19 selectively inhibit the 
function of mutated KRas without affecting cancer cells with RAS WT; however, its 
toxicity in healthy cells has not been proven [25].
3. Targeted drugs for PDE6δ inhibition
Post-translational modifications are important for the recognition and transport 
of KRas4B to the plasma membrane; therefore, the study of molecules responsible 
for recognizing these post-translational modifications may be an important thera-
peutic target against PDAC [26]. One of the proteins responsible for recognizing 
the post-translational modification is phosphodiesterase 6δ (PDE6δ), which 
recognizes the farnesylation or geranyl-geranylation present in the cysteine  of the 
CAAX motif of Kras4B protein [27]. A group of German researchers identified and 
evaluated the compound called Deltarasin, which interacts with PDE6δ, with a Kd 
of 38 nM, prevents the recognition of the post-translational modification pres-
ent in KRas4B, arresting KRas4B in the cytosol, and consequently preventing its 
activation and tumor progression. This compound was named the first generation 
of PDE6δ inhibitors [26]. However, its evaluation in noncancerous pancreatic duct 
cell lines showed high cytotoxicity; this affected considerably the cell viability at 
low concentrations [28]. In 2016, the analogue of the compound Deltarasin (second 
generation of PDE6δ inhibitors) was reported, and it was called deltazinone. This 
analogue presented constant dissociation of Kd 38 nM to Kd 4 nM, thus showing to 
be a compound with better interaction energy than the analogue of first generation. 
Deltazinone showed cytotoxic effects on pancreatic cancer cell lines at a concentra-
tion of 24 μM, but it took about 8 h to have an anti-proliferative effect on pancreatic 
cancer cell lines. Conversely, Deltarasin, at a concentration of 5 μM showed the 
same effect in 1 hour. Considering these data, the first generation of PDE6δ inhibi-
tors have a better performance than the ones from the second generation [29, 
30]. In 2017, the third generation of specific PDE6δ inhibitors, which were called 
Deltasonamides, was reported. This new generation shows more interaction energy 
than the ones from the first generation and greater cytotoxic effects on pancreatic 
cancer cell lines at concentrations from 1 to 12 μM [31].
In early 2019, drugs based on triazoles arose. These compounds can be considered 
as the fourth generation of PDE6δ inhibitors since they used the structure of Deltarasin 
to be able to find the functional group with the highest interaction energy with PDE6δ. 
This fourth generation is still in in vitro studies in order to evaluate its cytotoxic 
effect [32]. At the beginning of 2020, the fifth generation of PDE6δ inhibitors, called 
Deltaflexin, arose; although they are analogues of Deltarasin, they do not have the 
same cytotoxic effects showed by the first generation of PDE6δ inhibitors [33].
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4. Drugs capable of stabilizing the KRas4B/PDE6δ protein complex
The search for new targeted therapies aimed at trying to improve the quality 
of life of patients with pancreatic cancer has taken about 30 years; along this time, 
researchers have looked for compounds that can inhibit the signaling pathway of 
the KRas4B oncoprotein. One of the most important mechanisms for the activation 
of KRas4B is the transport from the cytosol toward the plasma membrane by the 
PDE6δ, which recognize the farnesyl group of KRas4B present at carboxyl terminal 
(Figure 1a). It was believed that KRas4B/PDE6δ was transported as a dimer, and 
it is now known that it forms a cluster of 6–12 proteins or 3–6 dimers (Figure 1b). 
Because of this, our work group looked for a plate of the heterodimer using the 
crystal of the heterodimeric complex of the cluster of 6 proteins (Figure 1c) in 
order to identify small organic molecules capable of stabilizing the interaction of 
the molecular complex KRas4B/PDE6δ with the purpose of avoiding the activa-
tion of KRas4B as well as its signaling pathway dependent of this oncoprotein. An 
exhaustive search was carried out in public chemical libraries of organic compounds 
Figure 1. 
Types of interactions between KRas4B/PDE6δ heterodimeric complex crystallized. (A) Interaction 
between K-Ras4B (pink) and PDE6δ (aqua) proteins. (B) Cluster formation among K-Ras4B/PDE6δ in 
multiheterodimeric molecular complexes crystallized. (C) Template of K-Ras4B/PDE6δ heterodimeric complex 
in a cluster used to docking and drug identification. (D) Molecular docking of D14 (N-[(2H-1,3-benzodioxol-
5-yl)methyl]-2-[4-(5-chloro-6-oxo-1-phenyl-1,6-dihydropyridazin-4-yl)piperazin-1-yl]acetamide) and C22 
(3-(2-{[1-(4 chlorophenyl)ethyl]amino}acetamido)-N-cyclopropylbenzamide) compounds and using a cluster 
of the heterodimeric K-Ras4B/PDE6δ molecular complexes.
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with pharmacological potential, which could stabilize the KRas4B/PDE6δ com-
plex. The identification of the compounds that had an in silico interaction with the 
complex, in addition these compounds was selected considering that they complied 
with the Lipinsky rule, which states that (1) the compounds should not have more 
than five hydrogen bridge donors; (2) they must not contain more than 10 hydrogen 
bridge acceptors; (3) they must have a molecular weight of less than 500 g/mol; 
(4) the compounds must have an octanol/water partition coefficient of less than 
five (log P < 5). Compounds identified as D14 and C22 showed different in silico 
interaction energies on the KRas4B/PDE6δ and K-Ras4BG12C/PDE6δ heterocom-
plex crystals; these interaction energies ranged from −143 to −162 ΔG [28].
An in silico analysis on the prediction of absorption using the ADME software 
made it possible to identify that compounds D14 and C22 have good absorption at 
the intestinal level and have low uptake by the permeability glycoprotein proteins 
that belong to the ABC transporter family. Their values are very low compared with 
the absorption of Gemcitabine and Deltarasin, which indicates that compounds 
D14 and C22 have a low chemoresistance when they are used as a treatment for 
pancreatic cancer cells (Figure 2a). Additionally, it was possible to observe a 
metabolism of compounds D14 and C22 by cytochromes P450 (CYP450), which 
indicated rapid liver metabolism and low toxicity since these compounds are coated 
by these enzymes (Figure 2b). Furthermore, it was observed that these compounds 
may have low toxicity compared to that obtained with the treatment of choice for 
pancreatic cancer such as Gemcitabine and with the PDE6δ Deltarasin inhibitor 
(Figure 2c).
Once identified that compounds D14 and C22 do not have toxic effects, we 
assessed the presence of KRas4B and PDE6d in pancreatic cancer cell lines by 
immunofluorescence using different cell lines with KRas4B (BxPC3), KRas4BG12D 
(PANC-1), and KRas4BG12C (MIA PaCa-2); we observed a greater presence of 
these proteins in the KRas PANC-1 and MIA PaCa-2-dependent cell lines (Figure 3). 
Having identified the cell lines with the highest presence of KRas4B and PDE6d, we 
treated them with a concentration of 200 μM of compounds D14 and C22 comparing 
their effect with hTERT-HPNE, which is a noncancerous cell line, and with 5 μM of 
Deltarasin (Figure 4). The results showed that compound D14 had a greater cyto-
toxic effect on the PANC-1 and MIA PaCa-2 cell lines, while compound C22 had a 
greater cytotoxic effect on the MIA PaCa-2 cell line. The comparison of these results 
with the effect obtained from Deltarasin, where the normal hTERT-HPNE cell line 
of pancreas was affected, suggested that our compounds do not have cytotoxicity in 
noncancerous cell lines.
Taking into account the results described above, we carried out Ras activation 
assays using the MIA PaCa-2 cell line. We obtained a dose response curve during 
60 min, measuring Ras-GTP uptake by means of G-Lisa assays. Compounds D14 and 
C22 significantly decreased Ras activation over time; we obtained a 50% decrease 
in Ras activation at 60 min after treatment with the compounds (Figure 5a). As 
mentioned earlier during this chapter, the constitutive activation of KRas4B is 
essential for the development, progression, and maintenance of pancreatic cancer, 
and therefore, we performed subcutaneous xenograft tests by grafting 5 million cells 
of the MIA PaCa-2 cell line and administered via intraperitoneal 10 and 20 mg/kg 
of weight of compounds D14 and C22 for 15 days. The result was a 50% decrease in 
tumor growth in tumors treated with 20 mg/kg of weight of the two compounds, 
compared to the vehicle used as a control (Figure 5b and c).
Pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of 
death by cancer, in addition to being one of the most aggressive types of cancer. The 
pancreatic cancer stem cell population (PCSCs) has been linked to this aggressive-
ness and poor prognosis. The cancer stem cell model proposes that tumor initiation, 
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maintenance, and growth are directed by the population of stem cancer cells (CSC) 
[34, 35], which have been identified in several types of cancer, e.g. breast, brain, 
head and neck, colon, and pancreas [36, 37]. CSCs are defined as those tumor cells 
Figure 2. 
Prediction of ADME processes of compounds D14 and C22. (A) Absorption of compounds D14 and C22 in 
epithelial barriers and their uptake by permeability glycoprotein proteins. (B) Metabolization of compounds 
D14 and C22 by means of cytochrome P450. (C) Toxicity of compounds D14 and C22.
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capable of self-renewal and production of heterogeneous lineages that comprise 
tumor volume [38]. In addition, several studies have reported evidence of the 
contribution of CSCs in resistance to conventional therapy, which causes metastasis 
and tumor recurrence [36, 39]. Different immunphenotypes have been reported 
for the identification of pancreatic cancer stem cells (PCSCs) [36, 37]. Due to the 
high fatality of PDAC, the importance of CSCs, and the participation of oncogenic 
KRas4B, we decided to evaluate the effect on the tumorigenicity of compounds D14 
and C22 in CSC of PDAC; in this sense, cancer steam cells from BxPC3, PANC-1, 
and MIA PaCa-2 pancreatic cancer cell lines, as well as in the hTERT-HPNE non-
cancerous cell line, were growing in nonadherent conditions, forming spheroids 
or pancreatospheres and selected with the immunophenotypes positive to CD44, 
CD24, and ESA markers, which indicates an enrichment of PCSC (Figure 6). These 
Figure 3. 




were treated with 49.65, 99.3, and 148.9 μM of compound D14, and with 494 nM of 
Gemcitabine. It was found that the treatment with compound D14 was able to break 
up the pancreatospheres formed by BxPC3 and MIA PaCa-2 more efficiently than 
the first-line treatment with Gemcitabine (Figure 7).
Figure 4. 
Morphological visualization of hTERT-HPNE, PANC-1, and MIA PaCa-2 cell lines treated with compounds 
D14 and C22 at 200 μM compared with the effect of Deltarasin.
Figure 5. 
Compounds D14 and C22 decrease the activation of Ras in the MIA PaCa-2 cell line promoting the decrease of 
tumor growth. (A) Ras activation decreases by more than 50% in the MIA PaCa-2 cell line treated with D14 
and C22. (B) and (C) Compounds D14 and C22 decrease tumor growth in subcutaneous xenograft models, 
using 20 mg/kg and 10 mg/kg intraperitoneally for 15 days.
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Figure 6. 
CD44, CD24, and ESA immunophenotype in 3D cultures of BxPC3, PANC-1, and MIA PaCa-2. The 
expression of these markers is crucial for the identification of the cancerous trunk population.
Figure 7. 
Morphological visualization of the effect of compound D14 on the viability of BxPC3 and MIA PaCa-2 in 2D 




The search for compounds that can stabilize the KRas4B/PDE6δ heterodimeric 
complex has provided a great pattern in the search for new and less toxic pharmaco-
logical alternatives for the treatment of pancreatic cancer and with fewer collateral 
effects due to their high specificity. Compounds D14 and C22 have shown great 
specific cytotoxic effects against pancreatic cancer cell lines as well as decreased 
tumor growth and, even better, in the possible reduction of the PCSC population. 
However, it is necessary to carry out additional experiments in order to identify the 
specific mechanisms of action of the cross-linking and stabilizing compounds of 
this protein multicomplex.
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